Spectrum of activity and mode of action of REP3123, a new antibiotic to treat Clostridium difficile infections

Journal of Antimicrobial Chemotherapy

Volumn 63, Issue 5, 2009, Pages 954-963

  Critchley, Ian A ^a   Green, Louis S ^a   Young, Casey L ^a   Bullard, James M ^a   Evans, Ron J ^a   Price, Melissa ^a   Jarvis, Thale C ^a   Guiles, Joseph W ^a   Janjic, Nebojsa ^a   Ochsner, Urs A ^a  

^a Replidyne Inc   (United States)

Author keywords

C. difficile infection; In vitro resistance development; Methionyl tRNA synthetase; Mode of action

Indexed keywords

ANTIBIOTIC AGENT; BACTERIAL ENZYME; CYTOPLASM PROTEIN; METHIONINE TRANSFER RNA LIGASE; METRONIDAZOLE; MITOCHONDRIAL ENZYME; MOXIFLOXACIN; NOVOBIOCIN; PSEUDOMONIC ACID; REP 3123; UNCLASSIFIED DRUG; VANCOMYCIN;

AMINO ACID SUBSTITUTION; ANTIBACTERIAL ACTIVITY; ANTIBIOTIC SENSITIVITY; ARTICLE; BACTERIAL STRAIN; BACTERIUM ISOLATE; BACTERIUM MUTANT; CELLULAR DISTRIBUTION; CLOSTRIDIUM DIFFICILE INFECTION; CONTROLLED STUDY; DRUG SPECIFICITY; DRUG TARGETING; ENTEROCOCCUS FAECALIS; ENTEROCOCCUS FAECIUM; ENZYME INHIBITOR INTERACTION; ENZYME LOCALIZATION; GENE OVEREXPRESSION; GRAM NEGATIVE BACTERIUM; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; POINT MUTATION; PROTEIN SYNTHESIS INHIBITION; STAPHYLOCOCCUS AUREUS; STREPTOCOCCUS PYOGENES; STRUCTURE ACTIVITY RELATION;

ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BENZOPYRANS; DRUG RESISTANCE, BACTERIAL; ENZYME INHIBITORS; GENE DOSAGE; GRAM-NEGATIVE BACTERIA; GRAM-POSITIVE BACTERIA; HUMANS; METHIONINE-TRNA LIGASE; MICROBIAL SENSITIVITY TESTS; POINT MUTATION; PROTEIN BIOSYNTHESIS; THIOPHENES;

EID: 64649099779     PISSN: 03057453     EISSN: 14602091     Source Type: Journal    
DOI: 10.1093/jac/dkp041     Document Type: Article

References (39)

1. McFarland LV. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat Clin Pract Gastroenterol Hepatol 2008; 5: 40-8.
2. Sunenshine RH, McDonald LC. Clostridium difficile-associated disease: New challenges from an established pathogen. Cleve Clin J Med 2006; 73: 187-97.
3. Owens RC Jr, Donskey CJ, Gaynes RP et al. Antimicrobial-associated risk factors for Clostridium difficile infection. Clin Infect Dis 2008; 46 Suppl 1: S19-31.
4. Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile associated disease in North America and Europe. Clin Microbiol Infect 2006; 12 Suppl 6: 2-18.
5. Settle CD, Wilcox MH. Review article: Antibiotic-induced Clostridium difficile infection. Aliment Pharmacol Ther 1996; 10: 835-41.
6. Archibald LK, Banerjee SN, Jarvis WR. Secular trends in hospital-acquired Clostridium difficile disease in the United States, 1987-2001. J Infect Dis 2004; 189: 1585-9.
7. Brazier JS. Clostridium difficile: From obscurity to superbug. Br J Biomed Sci 2008; 65: 39-44.
8. Pepin J, Valiquette L, Alary ME et al. Clostridium difficile associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. Can Med Assoc J 2004; 171 466-72.
9. Fawley WN, Underwood S, Freeman J et al. Efficacy of hospital cleaning agents and germicides against epidemic Clostridium difficile strains. Infect Control Hosp Epidemiol 2007; 28: 920-5.
10. McDonald LC, Killgore GE, Thompson A et al. An epidemic, toxin gene-variant strain of Clostridium difficile. N Engl J Med 2005; 353: 2433-41.
11. Warny M, Pepin J, Fang A et al. Toxin production by an emerging strain of Clostridium difficile associated with outbreaks of severe disease in North America and Europe. Lancet 2005; 366 1079-84.
12. Al-Nassir WN, Sethi AK, Li Y et al. Both oral metronidazole and oral vancomycin promote persistent overgrowth of vancomycin-resistant enterococci during treatment of Clostridium difficile-associated disease. Antimicrob Agents Chemother 2008; 52: 2403-6.
13. Bartlett JG. Clostridium difficile: Old new observations. J Clin Gastroenterol 2007; 41 Suppl 1: S24-9.
14. Zar FA, Bakkanagari SR, Moorthi KM et al. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile-associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302-7.
15. Gerber M. Ackermann G. OPT-80, a macrocyclic antimicrobial agent for the treatment of Clostridium difficile infections: A review. Expert Opin Investig Drugs 2008; 17: 547-53.
16. Freeman J, Baines SD, Jabes D et al. Comparison of the efficacy of ramoplanin and vancomycin in both in vitro and in vivo models of clindamycin-induced Clostridium difficile infection. J Antimicrob Chemother 2005; 56: 717-25.
17. Musher DM, Logan N, Hamill RJ et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006; 43: 421-7.
18. Weiss K. Toxin-binding treatment for Clostridium difficile: A review including reports of studies with tolevamer. Int J Antimicrob Agents 2009; 33: 4-7.
19. Stiefel U, Nerandzic MM, Koski P et al. Orally administered b-lactamase enzymes represent a novel strategy to prevent colonization by Clostridium difficile. J Antimicrob Chemother 2008; 62: 1105-8.
20. Dendukuri N, Costa V, McGregor M et al. Probiotic therapy for the prevention and treatment of Clostridium difficile-associated diarrhea: A systematic review. Can Med Assoc J 2005; 173: 167-70.
21. Citron DM, Warren YA, Tyrrell KL et al. Comparative in vitro activity of REP3123 against Clostridium difficile and other anaerobic intestinal bacteria. J Antimicrob Chemother 2009; 63 972-6.
22. Ochsner UA, Bell SJ, O'Leary AL et al. Inhibitory effect of REP3123 on toxin and spore formation in Clostridium difficile, and in vivo efficacy in a hamster gastrointestinal infection model. J Antimicrob Chemother 2009; 63: 964-71.
23. Hecht DW, Galang MA, Sambol SP et al. In vitro activities of 15 antimicrobial agents against 110 toxigenic Clostridium difficile clinical isolates collected from 1983 to 2004. Antimicrob Agents Chemother 2007; 51: 2716-9.
24. Clinical and Laboratory Standards Institute. Methods for Antimicrobial Susceptibility Testing of Anaerobic Bacteria - Seventh Edition: Approved Standard M11-A7. CLSI, Wayne, PA, USA, 2007.
25. Clinical and Laboratory Standards Institute. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically - Seventh Edition: Approved Standard M7-A7. CLSI, Wayne, PA, USA, 2006.
26. Green LS, Bullard JM, Ribble W et al. Potent and selective inhibition of methionyl-tRNA synthetase by REP8839. Antimicrob Agents Chemother 2009; 53: 86-94.
27. Ochsner UA, Young CL, Stone KC et al. Mode of action and biochemical characterization of REP8839, a novel inhibitor of methionyl-tRNA synthetase. Antimicrob Agents Chemother 2005; 49 4253-62.
28. Critchley IA, Young CL, Stone KC et al. Antibacterial activity of REP8839, a new antibiotic for topical use. Antimicrob Agents Chemother 2005; 49: 4247-52.
29. Gentry DR, Ingraham KA, Stanhope MJ et al. Variable sensitivity to bacterial methionyl-tRNA synthetase inhibitors reveals subpopulations of Streptococcus pneumoniae with two distinct methionyl-tRNA synthetase genes. Antimicrob Agents Chemother 2003; 47: 1784-9.
30. Mechulam Y, Schmitt E, Maveyraud L et al. Crystal structure of Escherichia coli methionyl-tRNA synthetase highlights species-specific features. J Mol Biol 1999; 294: 1287-97.
31. Bourgault AM, Lamothe F, Loo VG et al. In vitro susceptibility of Clostridium difficile clinical isolates from a multi-institutional outbreak in Southern Quebec, Canada. Antimicrob Agents Chemother 2006; 50: 3473-5.
32. Credito KL, Appelbaum PC. Activity of OPT-80, a novel macrocycle, compared with those of eight other agents against selected anaerobic species. Antimicrob Agents Chemother 2004; 48: 4430-4.
33. Baines SD, O'Connor R, Freeman J et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62: 1046-52.
34. Pelaez T, Alcala L, Alonso R et al. Reassessment of Clostridium difficile susceptibility to metronidazole and vancomycin. Antimicrob Agents Chemother 2002; 6: 1647-50.
35. Pelaez T, Cercenado E, Alcala L et al. Metronidazole resistance in Clostridium difficile is heterogeneous. J Clin Microbiol 2008; 46: 3028-32.
36. Drudy D, Quinn T, O'Mahony R et al. High-level resistance to moxifloxacin and gatifloxacin associated with a novel mutation in gyrB in toxin-A-negative, toxin-B-positive Clostridium difficile. J Antimicrob Chemother 2006; 58: 1264-7.
37. Spigaglia P, Barbanti F, Mastrantonio P et al. Fluoroquinolone resistance in Clostridium difficile isolates from a prospective study of C. difficile infections in Europe. J Med Microbiol 2008; 57: 784-9.
38. Noren T, Wullt M, Akerlund T et al. Frequent emergence of resistance in Clostridium difficile during treatment of C. difficile-associated diarrhea with fusidic acid. Antimicrob Agents Chemother 2006; 50: 3028-32.
39. O'Connor JR, Galang MA, Sambol SP et al. Rifampin and rifaximin resistance in clinical isolates of Clostridium difficile. Antimicrob Agents Chemother 2008; 52: 2813-7.